GBM AGILE Opens to Paxalisib in Canada
/PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the...
Stay updated with breaking news from Adaptive Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the...
The Sydney-based company’s flagship drug, paxalisib, is a candidate in a multi-drug platform study designed to identify promising new...
SYDNEY, Nov. 29, 2021 /PRNewswire/ – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to...
Form 20-F Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... | October 7, 2021
This study compares the effect of convalescent plasma vs no convalescent plasma on the outcome of organ support–free days in the hospital among critically ill a